ArticleCell & bioscience2025
ZNF146 accelerates lung adenocarcinoma progression through MDM2/p53 and PHGDH/ferroptosis.
Article in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting ZNF570 activates ferroptosis to reverse tamoxifen resistance in ER + breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- NSUN2 promotes colorectal cancer progression by stabilizing PHGDH mRNA to promote serine metabolism reprogramming.Cancer & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) remains a significant contributor to cancer incidence and mortality, with transcription factors playing pivotal roles in its progression and serving as potential therapeutic targets.
resultsThrough an extensive analysis of expression data from over a thousand LUAD samples, we identified zinc finger protein 146 (ZNF146) as a transcription factor significantly overexpressed in LUAD, closely associated with poor patient outcomes. Functional studies using knockout and re-expression experiments in LUAD cell lines confirmed that ZNF146 robustly promotes cell proliferation. RNA-seq and ChIP-seq data integration further revealed two key downstream effectors of ZNF146: murine double minute 2 homolog (MDM2) and phosphoglycerate dehydrogenase (PHGDH). Our results demonstrated that ZNF146 accelerates LUAD progression via the MDM2/p53 pathway and PHGDH-mediated regulation of ferroptosis.
conclusionsOur findings indicate that targeting ZNF146 could be an effective strategy in treating LUAD, supported by evidence from adeno-associated virus-mediated inhibition of ZNF146, which suppressed tumor growth in patient-derived organoids and xenograft models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.